This is a
2-part, study to determine the safety, tolerability and pharmacokinetics of
oral dabrafenib in pediatric subjects with advanced BRAF
mutation-positive solid tumors. Part 1 (dose escalation study) will identify
the recommended Part 2 (tumor-specific expansion study
To learn more about available clinical trials related to solid tumors, contact us at email@example.com or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2018 Cincinnati Children's Hospital Medical Center. All rights reserved.